These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 30295043

  • 21. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 22. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M, Eto M.
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [Abstract] [Full Text] [Related]

  • 23. Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer.
    Vaishampayan U.
    Curr Opin Oncol; 2014 May; 26(3):265-73. PubMed ID: 24626129
    [Abstract] [Full Text] [Related]

  • 24. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM, Radium-223 International Early Access Program Investigators.
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [Abstract] [Full Text] [Related]

  • 25. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    Kang YJ, Jang WS, Kwon JK, Yoon CY, Lee JY, Ham WS, Choi YD.
    BMC Cancer; 2017 Nov 23; 17(1):789. PubMed ID: 29169347
    [Abstract] [Full Text] [Related]

  • 26. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr 23; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 27. Progress in the treatment of advanced prostate cancer.
    Sternberg CN, Petrylak DP, Madan RA, Parker C.
    Am Soc Clin Oncol Educ Book; 2014 Apr 23; ():117-31. PubMed ID: 24857068
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K.
    Eur Urol; 2014 May 23; 65(5):875-83. PubMed ID: 24099659
    [Abstract] [Full Text] [Related]

  • 29. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M, Yokomizo A, Adachi T, Koga H, Yamaguchi A, Imada K, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S.
    Jpn J Clin Oncol; 2014 Sep 23; 44(9):860-7. PubMed ID: 24951829
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.
    Urol Oncol; 2013 Nov 23; 31(8):1457-63. PubMed ID: 22552048
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov 23; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 35. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr 23; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

  • 36. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M, Petrylak DP.
    Oncology (Williston Park); 2013 Nov 23; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [Abstract] [Full Text] [Related]

  • 37. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.
    Q J Nucl Med Mol Imaging; 2015 Dec 23; 59(4):400-10. PubMed ID: 26337241
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
    Küronya Z, Bíró K, Gyergyay F, Géczi L.
    Orv Hetil; 2017 Jan 23; 158(2):42-49. PubMed ID: 28088885
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.